Effets hémodynamiques de l’administration de vasopressine au décours de l’Arrêt Cardio-Respiratoire chez des patients en état de choc réfractaire Hemodynamic effects of vasopressin administration in patient with refractory shock following successfully resuscitated cardiac arrest

INTERVENTION: Trade Name: PITRESSIN Product Name: Arginine Vasopressine (Pitressin) Pharmaceutical Form: Intravenous infusion Other descriptive name: VASOPRESSIN Concentration unit: IU international unit(s) Concentration type: range Concentration number: 0.01 U/min‐0.06 UI/min CONDITION: Patients admitted in ICU after sucessfully resuscitated cardiac arrest and developping a refractory shock ; MedDRA version: 8.1 Level: LLT Classification code 10047146 Term: Vasopressin PRIMARY OUTCOME: Main Objective: A decrease of the need of vasopressor support. Primary end point(s): Decrease in the need of vasopressor support Secondary Objective: Evolution of venous oxygen saturation and organ dysfunction score (LOD, SOFA) INCLUSION CRITERIA: Patient admitted after successfully resuscitated cardiac arrest requiring high level of vasopressor support Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range